Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
Genocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.com
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned about 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent quarter. Institutional investors own 59.25% of the company's stock. Investment analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a report released on Friday. The firm set a "sell" rating on the biotechnology company's stock.
斯托克新闻网的投资分析师在周五发布的一份报告中开始报道Genocea Biosciences(纳斯达克：GNCA-GET评级)的股票。该公司对这家生物技术公司的股票设定了“卖出”评级。
Several other brokerages have also recently issued reports on GNCA. HC Wainwright cut Genocea Biosciences from a "buy" rating to a "neutral" rating in a research note on Friday, April 29th. Robert W. Baird decreased their price target on Genocea Biosciences from $8.00 to $3.00 in a research note on Monday, April 11th. Finally, Stifel Nicolaus lowered Genocea Biosciences from a "buy" rating to a "hold" rating in a research note on Friday, April 29th.
其他几家券商最近也发布了关于GNCA的报告。在4月29日星期五的一份研究报告中，HC Wainwright将Genocea Biosciences的评级从“买入”下调至“中性”。罗伯特·W·贝尔德在4月11日星期一的一份研究报告中将他们对Genocea Biosciences的目标价从8.00美元下调至3.00美元。最后，Stifel Nicolaus在4月29日星期五的一份研究报告中将Genocea Biosciences的评级从“买入”下调至“持有”。
GNCA stock opened at $0.01 on Friday. Genocea Biosciences has a 12-month low of $0.01 and a 12-month high of $2.24. The stock has a 50-day moving average price of $0.10 and a two-hundred day moving average price of $0.69. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. The company has a market cap of $828,149.40, a PE ratio of -0.02 and a beta of 2.26.
GNCA股票上周五开盘报0.01美元。Genocea Biosciences的12个月低点为0.01美元，12个月高位为2.24美元。该股的50日移动均线价格为0.10美元，200日移动均线价格为0.69美元。该公司的流动比率为1.35，速动比率为1.35，债务权益比率为0.24。该公司市值为828,149.40美元，市盈率为-0.02，贝塔系数为2.26。
An institutional investor recently raised its position in Genocea Biosciences stock. Commonwealth Equity Services LLC grew its holdings in shares of Genocea Biosciences, Inc. (NASDAQ:GNCA – Get Rating) by 49.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 31,981 shares of the biotechnology company's stock after purchasing an additional 10,576 shares during the period. Commonwealth Equity Services LLC owned about 0.06% of Genocea Biosciences worth $37,000 at the end of the most recent quarter. Institutional investors own 59.25% of the company's stock.
一家机构投资者最近提高了对Genocea Biosciences股票的头寸。根据最近提交给美国证券交易委员会的文件，Federal Equity Services LLC在第四季度增持了Genocea Biosciences，Inc.的股票(纳斯达克代码：GNCA-GET评级)49.4%。该机构投资者持有这家生物技术公司31,981股股票，在此期间又购买了10,576股。截至最近一个季度末，Federal Equity Services LLC拥有Genocea Biosciences约0.06%的股份，价值3.7万美元。机构投资者持有该公司59.25%的股份。
Genocea Biosciences Company Profile (Get Rating)
Genocea Biosciences公司简介(获取评级)
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.
Genocea Biosciences，Inc.是一家生物制药公司，发现和开发新型癌症免疫疗法。该公司使用其专有的发现平台ATLAS，该平台描述了每个患者对下一代肿瘤测序确定的每个目标或抗原的CD4+和CD8+T细胞免疫反应。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Genocea Biosciences (GNCA)
- Credo Technology Stock is Rebounding
- Investing In Preferred Stock vs. Common Stock
- Profiting From 52 Week Low Stocks
- Three Cheap Stocks The Insiders Are Buying
- Is Roblox A Good Play For The 2nd Half
- 免费获取StockNews.com关于基因组生物科学的研究报告(GNCA)
- 信实科技股正在反弹
- 投资优先股与普通股
- 从52周低点的股票中获利
- 内部人士正在买入的三只廉价股票
- 罗伯克斯是下半场的好球员吗？
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genocea生物科学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genocea Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。
